Icosavax ticks lower as HSR filing for AstraZeneca deal withdrawn, refiled

seekingalpha01-19

Icosavax (NASDAQ:ICVX) fell 1.7% as AstraZeneca (NASDAQ:AZN) withdrew its filing for HSR approval for the planned sale and refiled it. On Wednesday, the companies withdrew and refiled to give the ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2404507405?lang=en_US&edition=fundamental","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1250576655/image_1250576655.jpg","is_english":true,"pubTime":"2024-01-19 23:13","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"2404507405","market":"us","top_or_hot":-1,"title":"Icosavax ticks lower as HSR filing for AstraZeneca deal withdrawn, refiled","media":"seekingalpha","content":"<div>\n<p>Icosavax (NASDAQ:ICVX) fell 1.7% as AstraZeneca (NASDAQ:AZN) withdrew its filing for HSR approval for the planned sale and refiled it.  On Wednesday, the companies withdrew and refiled to give the ...</p>\n\n<a href=\"https://seekingalpha.com/news/4056469-icosavax-ticks-lower-as-hsr-filing-for-astrazeneca-deal-withdrawn-refiled\">Source Link</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Icosavax ticks lower as HSR filing for AstraZeneca deal withdrawn, refiled</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIcosavax ticks lower as HSR filing for AstraZeneca deal withdrawn, refiled\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-01-19 23:13 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/4056469-icosavax-ticks-lower-as-hsr-filing-for-astrazeneca-deal-withdrawn-refiled><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Icosavax (NASDAQ:ICVX) fell 1.7% as AstraZeneca (NASDAQ:AZN) withdrew its filing for HSR approval for the planned sale and refiled it.  On Wednesday, the companies withdrew and refiled to give the ...</p>\n\n<a href=\"https://seekingalpha.com/news/4056469-icosavax-ticks-lower-as-hsr-filing-for-astrazeneca-deal-withdrawn-refiled\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0208291251.USD","symbol_name":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) INC","start_time":0,"source_url":"https://seekingalpha.com/news/4056469-icosavax-ticks-lower-as-hsr-filing-for-astrazeneca-deal-withdrawn-refiled","article_id":"2404507405","we_media_id":null,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1250576655/image_1250576655.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2404507405","pubTimestamp":1705677235,"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"Icosavax  fell 1.7% as AstraZeneca  withdrew its filing for HSR approval for the planned sale and refiled it.  On Wednesday, the companies withdrew and refiled to give the Federal Trade Commission additional time to review the planned deal, according to a filing on Friday. The HSR waiting period now expires on Feb. 16.  AstraZeneca  agreed to acquire U.S. vaccine developer Icosavax  in a deal valued at up to $1.1 billion last month. The deal values Icosavax  at $15/share in cash at closing, plus a non-tradable contingent value right for up to $5/share in cash if certain milestones are met.  More on Icosavax  Icosavax CVR Seems Fairly Valued AstraZeneca: A $1.1B Shot In The Arm From Icosavax Acquisition Icosavax deal CVR based on FDA approval for IVX-A12, sales in EU, UK, Canada Biggest stock movers today: Oracle, Workhorse Group, Icosavax and more Seeking Alpha’s Quant Rating on Icosavax","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0208291251.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) INC","LU0082616367.USD":"摩根大通美国科技A（dist）","QID":"纳指两倍做空ETF","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU1803068979.SGD":"FTIF - Franklin Technology A (acc) SGD-H1","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","BK4568":"美国抗疫概念","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","LU1935042991.SGD":"MANULIFE GF GLOBAL MULTI-ASSET DIVERSIFIED INCOME  \"AA\" (SGDHDG) INC","BK4588":"碎股","LU0109392836.USD":"富兰克林科技股A","TQQQ":"纳指三倍做多ETF","LU0661504455.SGD":"Blackrock Global Equity Income A5 SGD-H","SQQQ":"纳指三倍做空ETF","LU0175139822.USD":"AB FCP I Global Equity Blend A USD","LU0130102774.USD":"Natixis Harris Associates US Equity RA USD","WKHS":"Workhorse Group, Inc.","QLD":"纳指两倍做多ETF","BK4581":"高盛持仓","LU2236285917.USD":"ALLIANZ GLOBAL INCOME \"AMG\" (USD) INC",".IXIC":"NASDAQ Composite","LU0648001328.SGD":"Natixis Harris Associates US Equity RA SGD","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","LU0965509283.SGD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (SGDHDG) INC","LU0289960550.SGD":"AB FCP I - GLOBAL EQUITY BLEND PORTFOLIO 'A' (SGD) ACC","QQQ":"纳指100ETF","LU0985489474.SGD":"First Eagle Amundi International AHS-C SGD-H","PSQ":"纳指反向ETF","LU0878866978.SGD":"First Eagle Amundi International AHS-QD SGD-H","ORCL":"甲骨文","LU0256863811.USD":"ALLIANZ US EQUITY \"A\" INC","BK4528":"SaaS概念","BK4539":"次新股","LU1201861249.SGD":"Natixis Harris Associates US Equity PA SGD-H","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus","LU0348723411.USD":"ALLIANZ GLOBAL HI-TECH GROWTH \"A\" (USD) INC","LU0980610538.SGD":"Natixis Harris Associates US Equity RA SGD-H","LU0433182093.SGD":"First Eagle Amundi International AS-C SGD","ICVX":"Icosavax, Inc.","LU1429558221.USD":"Natixis Loomis Sayles US Growth Equity RA USD","AZN":"阿斯利康","BK4534":"瑞士信贷持仓","BK4585":"ETF&股票定投概念","LU0068578508.USD":"First Eagle Amundi International Cl AU-C USD","BK4139":"生物科技","LU1506573853.SGD":"MANULIFE GF GLOBAL EQUITY \"AA\" (SGD) INC","LU1435385759.SGD":"Natixis Loomis Sayles US Growth Equity RA SGD-H"},"translate_title":"Icosavax股价下跌，HSR撤回并重新提交阿斯利康交易申请","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AZN":1,"ICVX":1,"WKHS":0.68,".IXIC":0.68,"ORCL":0.68,"PSQ":0.6,"QID":0.6,"QLD":0.6,"QQQ":0.6,"SQQQ":0.6,"TQQQ":0.6,"MNQmain":0.6,"NQmain":0.6},"content_text":"Icosavax (NASDAQ:ICVX) fell 1.7% as AstraZeneca (NASDAQ:AZN) withdrew its filing for HSR approval for the planned sale and refiled it.  On Wednesday, the companies withdrew and refiled to give the Federal Trade Commission additional time to review the planned deal, according to a filing on Friday. The HSR waiting period now expires on Feb. 16.  AstraZeneca (AZN) agreed to acquire U.S. vaccine developer Icosavax (ICVX) in a deal valued at up to $1.1 billion last month. The deal values Icosavax (ICVX) at $15/share in cash at closing, plus a non-tradable contingent value right for up to $5/share in cash if certain milestones are met.  More on Icosavax  Icosavax CVR Seems Fairly Valued AstraZeneca: A $1.1B Shot In The Arm From Icosavax Acquisition Icosavax deal CVR based on FDA approval for IVX-A12, sales in EU, UK, Canada Biggest stock movers today: Oracle, Workhorse Group, Icosavax and more Seeking Alpha’s Quant Rating on Icosavax","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.27.0","shortVersion":"4.27.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2404507405"}